End-stage Kidney Disease Clinical Trial
Official title:
Optimizing Kidney Transplant Patients' Informed Consent for Increased Risk Donors
Verified date | November 2015 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The objective of this study is to evaluate kidney transplant candidates' comprehension about increased risk donor kidneys necessary for informed consent. We have developed a web-based tool that educates and assesses candidates' comprehension (Inform Me), as a supplement to current informed consent processes. We will then compare the effectiveness of the current informed consent processes supplemented by Inform Me, with the current consent processes alone for kidney transplant.
Status | Completed |
Enrollment | 288 |
Est. completion date | November 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - English-speaking - 21 years or older - Kidney Transplant candidates eligible: 1) completed the first phase of transplant evaluation education, and 2) wait-listed patients expected to receive a transplant within the next 6 months, returning for re-evaluation. Exclusion Criteria: - No special classes of study participants, including fetuses, neonates, prisoners, institutionalized individuals, or other vulnerable populations will be included in the proposed study. Although pregnant women will be eligible for participation in the study, they are unlikely to be selected for kidney transplantation. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Northwestern Memorial Hospital | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Decisional conflict | Will measure difficulty in treatment decision-making. | 1 week | No |
Other | Satisfaction with the informed consent process | Assess decision-making quality, decision satisfaction, and perception of information. | 1 week | No |
Primary | Knowledge of increased risk donor kidney transplants | Assess knowledge of increased risk donor kidneys | 1 week | No |
Secondary | Willingness to accept an increased risk donor kidney transplant | Willingness to accept an increased risk donor kidney. | 1 week | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
Completed |
NCT02694068 -
Biological Determinants of Peritoneal Dialysis
|
||
Not yet recruiting |
NCT02832505 -
Applications of MRI in Kidney Disease
|
||
Not yet recruiting |
NCT02590081 -
Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00509236 -
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
|
Phase 3 | |
Completed |
NCT02009514 -
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
|
Phase 4 | |
Not yet recruiting |
NCT06377293 -
Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients
|
N/A | |
Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
Completed |
NCT01528800 -
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
|
Phase 2 | |
Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
Completed |
NCT04610593 -
Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis
|
N/A | |
Recruiting |
NCT05931276 -
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
|
Phase 3 | |
Completed |
NCT00143741 -
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
|
Phase 1 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Recruiting |
NCT03142529 -
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02342119 -
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
|
N/A | |
Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 | |
Recruiting |
NCT01111422 -
Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
|
Phase 4 |